Global and United States Hereditary Cancer Testing Market Report & Forecast 2022-2028

Hereditary cancer testing is a process of identifying an inherited gene mutation that increases the risk of cancer development. It mainly includes predictive genetic testing and clinical DNA sequencing, in predictive genetic testing, patient’s family history is analyzed for any inherited mutation from ancestry. In DNA sequencing, entire DNA or genome of an individual is analyzed. It is useful for testing many genetic mutations at a time.
Market Analysis and Insights: Global and United States Hereditary Cancer Testing Market
This report focuses on global and United States Hereditary Cancer Testing market, also covers the segmentation data of other regions in regional level and county level.
Due to the COVID-19 pandemic, the global Hereditary Cancer Testing market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, by Type, RNA Testing accounting for % of the Hereditary Cancer Testing global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While by Application, Breast Cancer was the leading segment, accounting for over percent market share in 2021, and altered to an % CAGR throughout this forecast period.
In United States the Hereditary Cancer Testing market size is expected to grow from US$ million in 2021 to US$ million by 2028, at a CAGR of % during the forecast period.
Global Hereditary Cancer Testing Scope and Market Size
Hereditary Cancer Testing market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Hereditary Cancer Testing market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
For United States market, this report focuses on the Hereditary Cancer Testing market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.

Segment by Type
RNA Testing
DNA Testing

Segment by Application
Breast Cancer
Gastrointestinal Cancer
Prostate Cancer
Respiratory/Lung Cancer
Other Cancers

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

By Company
Ambry Genetics (Konica Minota)
Asper Biogene
Natera
Caris Life Sciences
BioReference Laboratories (GeneDx)
LabSolutions
Progenity，Inc
ARUP Laboratories
Myriad
NeoGenomics
Blueprint Genetics
CellMax Life
Fulgent Genetics
Strand Life Sciences
Myogenes
LabCorp
Quest Diagnostics
Pathway Genomics